Latest news with #ValterPinto
Yahoo
a day ago
- Business
- Yahoo
NewLake Capital Partners to Participate in Upcoming June Conferences
NEW CANAAN, Conn., June 02, 2025 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OTCQX: NLCP) ('The Company' or 'NewLake'), a leading provider of real estate capital to state-licensed cannabis operators, today announced that management is scheduled to participate at the following June 2025 conferences. Benzinga Cannabis Capital ConferenceDates: June 8-10, 2025Location: Marriott Magnificent Mile, Chicago, ILPanel: Debt is Coming Due: How to Manage, Refinance, and Keep Lenders on Your SidePanel Date and Time: Monday, June 9, 2025, 10:35 a.m. CTLocation: 5th Floor - Chicago Ballroom ABCD Sidoti Virtual Small Cap ConferenceDates: June 11-12, 2025Presentation Date and Time: Thursday, June 12, 2025, 12:15 p.m. ETWebcast: Cannabis Europa LondonDates: June 24-25, 2025Panel: Capital at a Crossroads: Fixing Cannabis Finance in EuropePanel Date and Time: Tuesday, June 24, 2025, 9:40 a.m. ETLocation: The Barbican Centre, London To schedule a one-on-one meeting with NewLake's management team, please contact KCSA Strategic Communications at NewLake@ About NewLake Capital Partners, Capital Partners, Inc. is an internally-managed real estate investment trust ('REIT') that provides real estate capital to state-licensed cannabis operators through sale-leaseback transactions and third-party purchases and funding for build-to-suit projects. NewLake owns a portfolio of 34 properties comprised of 15 cultivation facilities and 19 dispensaries that are leased to single tenants on a triple-net basis. For more information, please visit Contact Information:Lisa MeyerChief Financial Officer, Treasurer and SecretaryNewLake Capital Partners, Investor Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsNewLake@ PH: (212) 896-1254 Media Contact:Ellen MellodyKCSA Strategic CommunicationsEMellody@ (570) 209-2947Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Q1 2025 RenovoRx Inc Earnings Call
Valter Pinto; Investor Relations; RenovoRx Inc Ramtin Agah; Chairman of the Board, Co-Founder, Chief Medical Officer; RenovoRx Inc Shaun Bagai; Chief Executive Officer, Director; RenovoRx Inc Ronald Kocak; Principal Financial Officer and Accounting Officer, Vice President, Controller; RenovoRx Inc Rafay Khalid; Analyst; Ascendiant Capital Markets Operator Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 financial and operational highlights conference call. All participants will be in a listen-only mode. (Operator Instructions) Please also note that today's event is being recorded. At this time, I'd like to turn the floor over to Valter Pinto, Managing Director at KCSA Strategic Communications. Sir, please go ahead. Valter Pinto Thank you, operator. Good afternoon, and welcome, everyone, to the RenovoRx first quarter 2025 conference call. I'm joined today by RenovoRx's leadership team, including Dr. Ramtin Agah, Founder and Chief Medical Officer; Shaun Bagai, Chief Executive Officer; and Ronald Kocak, VP Controller and Principal Accounting Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995 and applicable federal securities laws. And that actual results may differ materially and adversely from what is contemplated by such forward-looking statements due to a variety of substantial risks, uncertainties, and other factors. The company's forward-looking statements are based on management's current plans and assumptions and are subject to the risks and uncertainties more fully described in the company's filings with the SEC. These statements reflect management's view of current and future market conditions, including but not limited to statements regarding the company's clinical trials and other research studies, including timing for potential additional interim data readouts and full patient enrollment for RenovoRx's ongoing Phase 3 TIGeR-PaC clinical trials studying intra-arterial gemcitabine and locally advanced pancreatic cancer, the potential of the RenovoCath device as a standalone commercial product or the transarterial microperfusion therapy platform as a mechanism of action, the anticipated timing for and levels of revenue generation from RenovoCath sales and the company's commercialization plans in general, the potential for intra-arterial gemcitabine to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and RenovoRx's efforts to explore commercialization strategies utilizing the transarterial microperfusion therapy platform. For a detailed discussion of some of the material risks and uncertainties facing RenovoRx, I refer you to the company's annual report on Form 10-K for the year ended December 31, 2024, as well as the company's investor presentation and other reports filed periodically with the SEC, including our Form 10-Q for the first quarter of 2025, which was just filed with the SEC. RenovoRx disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. With that, it's my pleasure to turn the call over to Dr. Ramtin Agah, Founder and Chief Medical Officer of RenovoRx. Ramtin, please go ahead. Ramtin Agah Thank you, Valter, and good afternoon, everyone. I appreciate everyone joining us today. At RenovoRx, we're pioneering a new era in cancer care through our transarterial microperfusion or TAMP therapy platform. By localizing and targeting delivery of therapeutic agents, like chemotherapy, near the tumor site via the peripheral system, TAMP is designed to optimize drug concentration precisely where it's needed while potentially minimizing systemic exposure and related toxicities. This targeted approach addresses the longstanding challenge in cancer care where there is poor tumor blood supply. I believe TAMP represents a significant advancement in the way cancer treatment can be approached. Our mission is to transform patients' outcomes by providing a safer, more effective way to deliver therapy directly to heart-to-treat tumors. Our ongoing Phase 3 TIGeR-PaC clinical trial evaluating the targeted delivery of chemotherapy, gemcitabine, with TAMP via our patented FDA-cleared RenovoCath device to patients with locally advanced pancreatic cancer is advancing with encouraging results. Our initial interim data showed that the patients experienced median overall survival with standard systemic chemotherapy delivery of 10 months versus 16 months with our targeted approach. This is from the time of randomization. It is important to note that both median overall survival arms calculation for the study interim analysis data do not include approximately 5.5 months of life from diagnosis to randomization during the induction chemotherapy and radiation phase of the trial. Moreover, we observed a 65% reduction in adverse events such as nausea and fatigue, significantly improving patient quality of life. These results strengthen our conviction that TAMP can redefine outcomes for patients facing some of the most difficult-to-treat cancer. As we are continuing to increase exposure to TAMP and RenovoCath through our TIGeR-PaC trial and more recently to our commercial efforts for RenovoCath as a standalone device, the reception from physician community has been overwhelmingly positive. Clinical investigators have expressed strong support and enthusiasm to our approach in directly written, recognizing the potential clinical benefit and improved tolerability profile that the use of RenovoCath offers. Their feedback reinforces our belief that RenovoRx is well-positioned to establish a new standard of care for LAPC and potentially other indications. As we advance our clinical and commercialization efforts, I'm energized by the transformative potential of our platform and deeply appreciate your continued support as we work to change the future of cancer treatment. Thank you for attending and for your support of RenovoRx. With that, I turn it over to our CEO, Shaun Bagai. Shaun Bagai Thank you, Ramtin. Q1 of 2025 represented our first quarter of generating revenue from commercial sales. This is the result of the important strategic decision we made in 2024 to focus on implementing a commercial strategy for RenovoCath in tandem with our ongoing Phase 3 trial. We plan to launch our commercial efforts for RenovoCath during Q1 of this year in response to anticipated strong demand for our technology. However, we received purchase orders ahead of schedule generating $43,000 of revenue in December. I'm proud of our team for quickly implementing a go-to-market strategy to meet the demand from the oncology community and therefore made the decision to increase our US-based RenovoCath production last year. Last month, I stated that we expected Q1 revenue to be in a low six-figure range, followed by sequential quarter-over-quarter increases for the remainder of the year. I'm pleased to report that revenue from RenovoCath exceeded our internal expectations to approximately $200,000 in the first quarter, and we anticipate this trend to continue going forward with sequential quarterly growth for the foreseeable future. We are encouraged by the strong organic demand for RenovoCath with more than 10 medical institutions that are not current TIGeR-PaC sites having initiated the process for RenovoCath purchase orders. These include several esteemed high-volume academic and community and National Cancer Institute designated centers. Further, we believe the approximately 20 centers that have used RenovoCath as part of our TIGeR-PaC trial could also be potential customers for RenovoCath after completion of TIGeR-PaC enrollment anticipated for later this year. Additionally, early utilization of RenovoCath devices by initial customers has led to repeat purchase orders. Based on our internal analysis of clinical interest and FDA-cleared applications of the device, we believe that our initial total addressable market for RenovoCath represents an estimated $400 million peak US annual sales opportunity. We are assuming an average of eight annual procedures per patient and 7,000 initial target patients at peak market penetration in patient populations where we already have clinical usage. While we haven't publicly disclosed our catheter pricing, technologies utilizing the same reimbursement coding are charging between $6,500 and $8,500 per device. Looking ahead, we see expansion opportunities across other cancer indications that could create the potential for a several-billion-dollar US TAM for RenovoCath over time. The prospect of generating even a small portion of this market combined with the potential to help so many patients is driving our excitement about this opportunity. We believe we can manage meaningful market penetration with a small yet focused commercial team targeting the top 200 high-volume treatment centers. Importantly, we believe this strategy can be executed without a material increase in our expenses, whether through direct commercialization or by partnering with a larger organization with an established sales force, which is a strategy we are actively exploring. We expect that the growing revenues from RenovoCath will reduce our burn rate and that our cash on hand of $14.6 million at the end of the first quarter will fully fund both our RenovoCath scale-up and the continued progress of our Phase 3 TIGeR-PaC clinical trial. On the topic of our TIGeR-PaC clinical trial, during the first quarter of 2025, we announced that Johns Hopkins Medicine has now initiated enrollment in our ongoing Phase 3 TIGeR-PaC trial. This is a valuable addition to the distinguished network of clinical cancer sites across the US participating in this important trial as we work towards full enrollment. We are continuing to target additional sites and expect that TIGeR-PaC will achieve full enrollment during 2025. As a reminder, the current protocol and statistical analysis plan for the TIGeR-PaC trial requires 114 randomized patients with 86 events or deaths necessary to complete the final analysis. As of May 2, 2025, 91 patients have been randomized and 56 events have occurred, triggering the second interim analysis. We expect the Studies Data Monitoring Committee to review the data in Q3 and eagerly await their recommendations and feedback. Last week, we announced the issuance of a new US patent for our TAMP therapy platform, further enhancing our IP production. RenovoRx's strong and growing intellectual property portfolio provides key support to the company's continuing commercialization of RenovoCath. The issuance of this new patent highlights the innovation behind our TAMP therapy platform and strengthens our competitive position. Before closing, I want to highlight one final point. During the first quarter, we announced that in our most recent open trading window, members of the management team and board purchased an aggregate of approximately 143,000 shares of RenovoRx stock and multiple open market purchases. This signals our confidence in our company and its future and underscores our enthusiasm for our company's long-term value proposition. In conclusion, I want to reaffirm our belief that the approximately 20 cancer centers that have used RenovoCath as part of our TIGeR-PaC trial could also be potential customers after the planned completion of enrollment later this year. Building upon our recent success, we expect revenue from RenovoCath to increase from the low six-figure range with sequential quarter-over-quarter increases for the remainder of the year as we move along the path to becoming a cash flow positive in the future. With that, I'll turn it over to Ron, who will take us through some of the numbers. Ronald Kocak Thank you, Shaun. For the first quarter of 2025, Renovo reported revenue of approximately $200,000 from commercial sales of its FDA-cleared RenovoCath device, exceeding our initial expectations in our first quarter of revenue. Research and development expenses were $1.7 million for the quarter, up from $1.3 million in the first quarter of 2024. This $0.4 million increase was primarily driven by the following; higher employee compensation due to cost-of-living adjustments, increased manufacturing and nonrecurring engineering costs to support commercial scale-up, greater participation in conferences and trade shows, and other ongoing R&D activities. Selling, general, and administrative expenses were approximately $1.6 million for the quarter, an increase from $1.2 million in the prior year period. This $0.4 million rise was attributed to increase in personnel-related costs, professional and consulting fees to support commercializations, and other selling, general, and administrative activities. As of March 31, 2025, the company had $14.6 million in cash and cash equivalent. As of May 9, 2025, shares of our common stock outstanding totaled 36,572,232. And now, I'll turn the call back to the operator for Q&A. Operator Ladies and gentlemen, at this time, we'll begin the question and answer session. (Operator Instructions) And in showing no questions, I would like to turn the floor back over to Shaun Bagai for closing comments. Shaun Bagai Thank you all again for participating in today's presentation. We were very excited about the key strategic steps we've taken over the last year to build long-term value in our company. And we are beginning to see the tangible results from these efforts. We look forward to the rest of the year unfolding and to providing you with important updates on our progress. Have a great evening. Operator And ladies and gentlemen, with that, we'll conclude today's conference call and presentation. We do thank you for joining. Actually, one moment, we do have someone that has joined the question queue. Let me join in Rafay Khalid from Ascendiant Capital Markets. Please go ahead with your question. Rafay Khalid Hi. Thank you. This is Rafay for Edward Woo, Ascendiant Capital Markets. Can you talk about your plans for the RenovoCath for international markets? Shaun Bagai At this point, we don't have a current CE mark. We're looking into that for the future. We haven't disclosed publicly on timing of international markets, but obviously, there's high demand for this type of technology given the unmet need in these types of tumors in both the European countries as well as a very large market in China, Korea, and Japan as well. So there's interest there. We've talked to positions, but we plan on really driving hard on the US commercial market given the reimbursement landscape and then approaching outside the US markets exploring that later this year, potentially next year. Rafay Khalid Great. And one more question. Do you have plans to increase -- you talked about partnering with potentially the top 200 cancer centers? Would you use their sales force or would you use distributors to target those partners? Shaun Bagai I have stated publicly that we are talking to a handful of strategic partners. These are large companies that have sales forces that cater to the interventional oncologists who do the procedures or the interventional radiologists. So we're looking at, from a business perspective, if it makes more sense to hire a small sales force with a handful of reps to get to drive meaningful revenue for the company and or partner with a strategic partner that has an existing distribution channel. So we're exploring both currently and both are actually well on their way in terms of proving out which plan makes the most financial sense to the company. Operator (Operator Instructions) And ladies and gentlemen, at this time, I will turn it back to Mr. Bagai for any additional closing comments. Shaun Bagai Thank you again for your time and participating, and have a great evening. Thank you, everyone. Operator And that will conclude today's conference call presentation. Thank you for joining. You may now disconnect your lines. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Q1 2025 SRx Health Solutions, Inc. Earnings Call
Valter Pinto; Managing Director; SRx Health Solutions, Inc. Kent Cunningham; Chief Executive Officer; SRx Health Solutions, Inc. Nina Martinez; Chief Financial Officer; SRx Health Solutions, Inc. Operator Good day and welcome to the SRx Health Solutions 2025 first quarter financial results conference call. (Operator Instructions) Please note, this event has been recorded. I would now like to turn the conference over to Mr. Valter Pinto, Managing Director. Please go ahead. Valter Pinto Thank you, operator, and welcome everyone to the SRx Health Solutions first quarter 2025 financial results conference call. Joining me today are Ken Cunningham, Chief Executive Officer; Nina Martinez, Chief Financial Officer. The company's financial results press release has been posted to the Investor Relations section of the website, and our Form 10-Q will be filed with the SEC. Please note that remarks made today may include forward-looking statements subject to a variety of assumptions, risks, and uncertainties. The company's actual results may differ materially from those contemplated by such statements. For more detailed discussion, please refer to the forward-looking statements in the company's financial results press release and SEC filings. Also during the call today, we will discuss our non-GAAP financial measures. Reconciliations of these non-GAAP items to the most directly comparable GAAP financial measures will be provided in the company's press release and made available on the Investor Relations section of the company's website. I'd now like to turn the call over to Kent Cunningham. Kent, please go ahead. Kent Cunningham Thank you, Valter, and thank you everyone for joining us today to discuss our first quarter, 2025 financial and operating results. I'm joined on today's call by Nina Martinez, our Chief Financial Officer. I'll give a business update and then Nina will cover our financials in more detail. The first quarter of 2025 represents our last full quarter of financial results from only our Halo brand. Our merger with SRx closed on April 24, 2025, and thus going forward will report consolidated financial results for our Halo brand and SRx Health. For the first quarter of 2025, our pet food business generated $7.2 million in net sales, and we delivered gross profit margins of 33%, which stayed consistent year-over-year. During the quarter, international sales accounted for approximately 56% of total revenue. In April, we closed on the sale of Halo Asia for $8.1 million in total gross proceeds, which includes $6.5 million in cash at closing, along with a 3% royalty on sales over the next five years guaranteed by a minimum royalty payment of $330,000 per year or $1.65 million in total. We also agreed in principle to a 5.5% royalty agreement in Asia with our existing partner on all sales of the Halo Elevate brand. Despite quarterly sales decreasing year over year, Halo's performance was highlighted by 10% point of sale growth year over year across our primary digital platforms, Amazon and Chewy. This is promising for Halo as we've implemented strategic initiatives to increase the brand's share of voice, awareness, and new to brand consumers. We also launched a peanut butter main meal product, an extension of our top selling vegan sublimes, the first shipments to PetSmart Canada in the quarter. The pet food category continues to show resiliency as pet ownership continues to increase and consumer spending continues to rise with the macro trends of pet humanization, premiumization, and wellness underpinning industry growth, and Halo continues to offer a unique brand positioned for the health conscious consumer seeking the best nutrition for their pets. During the quarter, we sustained improvement in fill rates to an average fill rate of 98% for the quarter. We realized volume-based cost efficiencies with our co-manufacturing partners resulting in a 33% gross margin consistent with Q1 of last year. We're working closely with our partners to monitor tariff impacts, and minimal impact is expected as the vast majority of our ingredients and packaging are sourced domestically. We continue to effectively manage our inventory levels with a reduction of approximately 50% in the last 15 months. SG&A also improved dramatically year-over-year, decreasing from $5.1 million to $3.5 million. The decrease was driven primarily by lower marketing and advertising agency fees related to the Halo brand renovation, as well as decreased marketing spend in our international channel. Profitability improved as a result of all the strategic shifts made over the last 12 months. Therefore, our adjusted EBITDA loss improved 54% year-over-year to a loss of approximately $600,000 compared to a loss of $1.4 million in Q1 of last year. In conclusion, we've executed a digital first strategy in our domestic business and have continued our marketing investment focus to grow brand awareness and discoverability. We're now focused on optimizing our portfolio and addressing consumer barriers to purchase as we continue to move the business toward profitable growth. Now let me turn it over to Nina to take you through our financials in more detail. Nina Martinez Thanks, Kent, and good afternoon, everyone. Our Q1 2025 net revenue totaled $7.2 million, which is down 9% year-over-year. This decrease in net sales for the three months ended March 31 is primarily attributable to the shutdown of the unprofitable direct to consumer revenue stream in the second quarter of 2024. During the three months ended March 31, gross profit decreased 9% to $2.4 million. However, gross margins stayed consistent at 33% for the quarter compared to Q1 of '24. We continue to actively work with our co-manufacturing and freight partners to generate future cost savings and realize improved gross margins in future periods. We can see continued margin variability due to the current economic environment and pricing pressures due to inflationary costs for both ingredients and transportation. We will continue to refine and optimize our overall pricing strategy as we evaluate the future impact of inflation and tariffs to align ourselves with the market. We significantly reduced operating expenses in Q1 of '25 with an overall SG&A reduction of 32% as a result of our operating discipline and leverage we've created in the business. Sales and marketing costs decreased approximately 42% as we've improved the efficiency and ROI of our marketing investments. Employee compensation costs decreased approximately 23%, primarily related to reduction in headcount. Outbound freight decreased 96% during the quarter as a result of the shutdown of our DTC channel in June of '24. Share-based compensation decreased 46%, driven by a decrease in the annual board grant, which was postponed until the second quarter. Other G&A costs decreased 20%, driven by a reduction in transaction-related professional fees. The first quarter '25 net loss improved 66% year-over-year to $1 million compared to a $2.83 million loss in the first quarter of '24. Our Q1 2025 EPS came in at a loss per share of $0.37, a significant improvement of 90% from the $3.60 loss per share in Q1 of last year. Furthermore, as Kent highlighted, in Q1 are adjusted EBITDA loss and proved to a loss of $650,000 as compared to $1.4 million in the first quarter of 2024 and $700,000 in Q4 of '24. This is a testament to Halo's vastly positive turnaround. These improvements highlight our focus on driving operational leverage and positioning the company for continued profitability in the coming quarters. As for liquidity and capital resources, our cash and cash equivalents as of March 31 were $1.1 million and we achieved a networking capital position of $7.2 million. We generated cash and operations of approximately $400,000 a significant improvement from cash used in operations of $1 million in the same quarter last year. This is primarily driven by efficient working capital improvements. Cash used in investing activities was $1.1 million during the quarter, driven by our investment into SRx pre-merger recorded as note receivables on our balance sheet. Cash used in financing activities was $1.2 million during the quarter directly related to net repayments on our line of credit. As Kent mentioned, future filings and financial results reported will include the consolidated results for SRx Health and for our legacy Halo brand. Now that the merger has closed. We are optimistic about the future of the company. We look forward to updating the market in the coming months. I would now like to open the call for questions. Operator? Operator (Operator Instructions) As there are no questions, this concludes a question and answer session and today's conference. Thank you for attending today's presentation. You may not disconnect. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-05-2025
- Business
- Yahoo
SRx Health Solutions to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
SRx Health Solutions, Inc. TAMPA, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the 'Company'), a leading global health and wellness company, today announced it will host a conference call and webcast on Thursday, May 15, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025 and provide a business update. Conference Call and Webcast Information: Event: First Quarter 2025 Financial Results Conference Call Date: Thursday, May 15, 2025 Time: 4:30 p.m. Eastern Time Live Call: 1-844-825-9789 or 1-412-317-5180 Webcast: For interested individuals unable to join the conference call, the webcast replay of the call will be available for 90 days under the 'Events' section of the Company website by visiting About SRx Health Solutions, Inc. SRx Health Solutions Inc. is an integrated Canadian healthcare services provider that operates within the specialty healthcare industry. The SRx network extends across all ten Canadian provinces, making it one of the most accessible providers of comprehensive, integrated, and customized specialty healthcare services in the country. SRx combines years of industry knowledge, technology, and patient-centric focus to create strategies and solutions that consistently exceed client expectations and drive critical patient care initiatives aimed to improve the wellness of Canadians. For more information on SRx Health Solutions Inc., please visit Company Contact: SRx Health Solutions, Inc. Adesh A. Vora, Chairman Investor Contact: KCSA Strategic Communications Valter Pinto, Managing Director T: 212-896-1254 Valter@
Yahoo
10-04-2025
- Business
- Yahoo
NewLake Capital Partners to Host First Quarter 2025 Earnings Call on May 8th at 11:00 a.m. ET
NEW CANAAN, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OTCQX: NLCP) ('The Company' or 'NewLake'), a leading provider of real estate capital to state-licensed cannabis operators, today announced that it plans to host a conference call and report its financial results for the first quarter ended March 31, 2025 on Thursday, May 8, 2025. Additional details are available under the Investor Relations section of the Company's website: Event: NewLake Capital Partners First Quarter 2025 Earnings Call Date: Thursday, May 8, 2025 Time: 11:00 a.m. Eastern Time Live Call: 1-877-407-3982 (U.S. Toll-Free) or 1- 201-493-6780 (International) Webcast: For interested individuals unable to join the conference call, a dial-in replay of the call will be available until May 22, 2025, and can be accessed by dialing 1 -844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International) and entering replay pin number: 13752702. About NewLake Capital Partners, Capital Partners, Inc. is an internally managed real estate investment trust ('REIT') that provides real estate capital to state-licensed cannabis operators through sale-leaseback transactions and third-party purchases and funding for build-to-suit projects. NewLake owns a portfolio of 33 properties comprised of 15 cultivation facilities and 18 dispensaries that are leased to single tenants on a triple-net basis. For more information, please visit Contact Information:Lisa MeyerChief Financial Officer, Treasurer and SecretaryNewLake Capital Partners, Investor Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsNewLake@ PH: (212) 896-1254 Media Contact:Ellen MelodyKCSA Strategic CommunicationsEMellody@ (570) 209-2947Sign in to access your portfolio
